Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient

Department of Urology, Dresden University of Technology, Dresden, Germany.
International Journal of Cancer (Impact Factor: 5.09). 07/2009; 125(2):474-82. DOI: 10.1002/ijc.24353
Source: PubMed


Our understanding of metastatic spread is limited and molecular mechanisms causing particular characteristics of metastasis are largely unknown. Herein, transcriptome-wide expression profiles of a unique cohort of 20 laser-resected pulmonary metastases (Mets) of 18 patients with clear-cell renal cell carcinoma (RCC) were analyzed to identify expression patterns associated with two important prognostic factors in RCC: the disease-free interval (DFI) after nephrectomy and the number of Mets per patient. Differentially expressed genes were identified by comparing early (DFI < or = 9 months) and late (DFI > or = 5 years) Mets, and Mets derived from patients with few (< or =8) and multiple (> or =16) Mets. Early and late Mets could be separated by the expression of genes involved in metastasis-associated processes, such as angiogenesis, cell migration and adhesion (e.g., PECAM1, KDR). Samples from patients with multiple Mets showed an elevated expression of genes associated with cell division and cell cycle (e.g., PBK, BIRC5, PTTG1) which indicates that a high number of Mets might result from an increased growth potential. Minimal sets of genes for the prediction of the DFI and the number of Mets per patient were identified. Microarray results were confirmed by quantitative PCR by including nine further pulmonary Mets of RCC. In summary, we showed that subgroups of Mets are distinguishable based on their expression profiles, which reflect the DFI and the number of Mets of a patient. To what extent the identified molecular factors contribute to the development of these characteristics of metastatic spread needs to be analyzed in further studies.

Download full-text


Available from: Matthias Meinhardt, Jan 02, 2015
  • Source
    • "Overexpression of PTTG1 enhances the cell proliferation, migration, invasion, and/or tumorigenicity and the induction of aneuploidy of cells derived from cancers of the human pituitary, kidney, esophagus, breast, head, and neck, liver, thyroid, lung, etc (Solbach et al., 2004; Zhou et al., 2005; Kim et al., 2006; Malik and Kakar, 2006; Rehfeld et al., 2006; Solbach et al., 2006; Wuttig et al., 2009; Liang et al., 2011). PTTG1 overexpression correlates with metastasis and poor overall survival in various human cancers (Heaney et al., 2000; Malik and Kakar, 2006; Wuttig et al., 2009), and decreasing PTTG expression through PTTG siRNA inhibits tumor growth in ovarian (El-Naggar et al., 2007), hepatic (Cho-Rok et al., 2006). And lung (Kakar and Malik, 2006) cancer cell lines, indicating that PTTG1 may be a new therapeutic target for cancer treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the prognostic value of pituitary tumor transforming gene 1 (PTTG1) expression according to clinicopathological features among localized or locally advanced prostate cancer cases receiving hormone therapy. A retrospective study involved 64 patients receiving combined androgen blockade treatment was performed. PTTG1 expression was determined by immunohistochemical staining using initial needle biopsy specimens for diagnosis. Associations of PTTG1 with various clinicopathological features and disease-free survival were examined via uni- and multivariate analyses. No association between PTTG1 expression and clinical T stage, Gleason score, pretreatment PSA levels, risk groups was found (p =0.682, 0.184, 0.487, 0.571, respectively). Univariate analysis revealed that increased PTTG1 expression, T3 stage and high risk group were associated with increased risk of disease progression (p =0.000, 0.042, and 0.001), and high PSA level had a tendency to predict disease progression (p =0.056). Cox hazard ratio analysis showed that PTTG1 low expression (p =0.002), PTTG1 high expression (p =0.000) and high risk group (p =0.0147) were significantly related to decreased disease- free survival. In conclusion, PTTG1 expression determined by immunohistochemical staining in needle biopsy specimens for diagnosis is a negative prognostic factor for progression in localized or locally advanced prostate cancer receiving hormone therapy.
    Preview · Article · Jul 2012 · Asian Pacific journal of cancer prevention: APJCP
  • Source
    • "Gene expression datasets utilized were the public pre-processed datasets that included six cancer types and 10 datasets in total: colorectal cancer (Lin07 [25], Barrier06 [44]), breast cancer (Wang05 [36], Van02 [28]), clear-cell renal cell carcinoma (ccRCC, Jones05 [45], Wuttig09 [46]), non-small cell lung cancer(NSCLC, Sanchez10 [38], Beer02 [39]), melanoma (Riker08 [47]), gliomas(Freije04 [48]) (details were provided in Table 1). Missing values for each probe were filled by applied R package ‘impute’ [49]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Identification of driver mutations among numerous genomic alternations remains a critical challenge to the elucidation of the underlying mechanisms of cancer. Because driver mutations by definition are associated with a greater number of cancer phenotypes compared to other mutations, we hypothesized that driver mutations could more easily be identified once the genotype-phenotype correlations are detected across tumor samples. In this study, we describe a novel network analysis to identify the driver mutation through integrating both cancer genomes and transcriptomes. Our method successfully identified a significant genotype-phenotype change correlation in all six solid tumor types and revealed core modules that contain both significantly enriched somatic mutations and aberrant expression changes specific to tumor development. Moreover, we found that the majority of these core modules contained well known cancer driver mutations, and that their mutated genes tended to occur at hub genes with central regulatory roles. In these mutated genes, the majority were cancer-type specific and exhibited a closer relationship within the same cancer type rather than across cancer types. The remaining mutated genes that exist in multiple cancer types led to two cancer type clusters, one cluster consisted of three neural derived or related cancer types, and the other cluster consisted of two adenoma cancer types. Our approach can successfully identify the candidate drivers from the core modules. Comprehensive network analysis on the core modules potentially provides critical insights into convergent cancer development in different organs.
    Full-text · Article · Jun 2012 · BMC Systems Biology
  • Source
    • "These large mRNA profiles have been particularly successful in breast cancer [Andre and Pusztai, 2006; Chang et al. 2005; Weigelt et al. 2005; Ayers et al. 2004; Paik et al. 2004, 2006; Van De Vijver et al. 2002; Van &apos;t Veer et al. 2002] and colorectal cancer [Anjomshoaa et al. 2008; Garman et al. 2008; Lin et al. 2007a, 2007b; Alvarado et al. 2006; Gordon et al. 2006; Vallbohmer et al. 2006; Ahmed, 2005; Shih et al. 2005; Arango et al. 2004; Li et al. 2004; Huerta et al. 2003; Mariadason et al. 2003; Galon et al. 2002; Hegde et al. 2001]. However, they have also been applied to several other tumor types [Mengual et al. 2009; Wuttig et al. 2009; Bloomston et al. 2007; Jaeger et al. 2007; Mandruzzato et al. 2006; Winnepenninckx et al. 2006] including tumors of unknown origin [Van Laar et al. 2009]. Profiles have also been generated that can predict the progression of several different tumor types [Basil et al. 2006]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.
    Full-text · Article · Mar 2010 · rapeutic Advances in Medical Oncology, The
Show more